These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12433707)

  • 1. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.
    Lin HJ; Lakkides KM; Keku TO; Reddy ST; Louie AD; Kau IH; Zhou H; Gim JS; Ma HL; Matthies CF; Dai A; Huang HF; Materi AM; Lin JH; Frankl HD; Lee ER; Hardy SI; Herschman HR; Henderson BE; Kolonel LN; Le Marchand L; Garavito RM; Sandler RS; Haile RW; Smith WL
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1305-15. PubMed ID: 12433707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for colon neoplasia susceptibility variants at the human Cox2 locus.
    Ulrich CM; Potter JD
    J Natl Cancer Inst; 2001 Oct; 93(20):1572-4. PubMed ID: 11604482
    [No Abstract]   [Full Text] [Related]  

  • 3. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk.
    Goodman JE; Bowman ED; Chanock SJ; Alberg AJ; Harris CC
    Carcinogenesis; 2004 Dec; 25(12):2467-72. PubMed ID: 15308583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
    Ulrich CM; Whitton J; Yu JH; Sibert J; Sparks R; Potter JD; Bigler J
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):616-9. PubMed ID: 15767339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective].
    Kleibeuker JH; de Vries EG
    Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2203-7. PubMed ID: 14640056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations.
    Ulrich CM; Bigler J; Sibert J; Greene EA; Sparks R; Carlson CS; Potter JD
    Hum Mutat; 2002 Nov; 20(5):409-10. PubMed ID: 12402351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
    Szczeklik A; Sanak M
    Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
    Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAIDs to prevent colorectal cancer: a question of sensitivity.
    Elder DJ; Paraskeva C
    Gastroenterology; 1997 Dec; 113(6):1999-2003. PubMed ID: 9394741
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer.
    Cox DG; Pontes C; Guino E; Navarro M; Osorio A; Canzian F; Moreno V;
    Br J Cancer; 2004 Jul; 91(2):339-43. PubMed ID: 15173859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
    Crew TE; Elder DJ; Paraskeva C
    Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
    Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
    J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials.
    Hawk ET; Viner JL; Umar A
    Prog Exp Tumor Res; 2003; 37():210-42. PubMed ID: 12795057
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic variation in cyclooxygenase 1: effects on response to aspirin.
    Halushka MK; Walker LP; Halushka PV
    Clin Pharmacol Ther; 2003 Jan; 73(1):122-30. PubMed ID: 12545150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.
    Vogiagis D; Brown W; Glare EM; O'Brien PE
    Carcinogenesis; 2001 Jun; 22(6):869-74. PubMed ID: 11375891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prophylaxis of colorectal cancer with non steroidal anti-inflammatory drugs- a new reality?].
    Cijevschi C; Rezmireş A; Mintescu E; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):35-40. PubMed ID: 12635357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.